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ABSTRACT 
ColostrininTM (CLN), a complex mixture of proline-rich polypeptides derived from 
colostrums, can alleviate cognitive decline in early Alzheimer’s disease patients. The 
molecular basis of the action of CLN has been studied in vitro using human neuroblastoma 
cell lines. The aim of the present study was to use quantitative immunocytochemistry and 
immunoblotting to investigate the ability of CLN to relieve amyloid-β (Aβ)-induced 
cytotoxicity in rat primary hippocampal neuronal cells. Our data confirm that CLN alleviates 
the effect of Aβ-induced cytotoxicity and causes a significant reduction in the elevated levels 
of the antioxidant enzyme SOD1. 
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Alzheimer’s disease is the most common form of dementia, affecting 18 million people 
worldwide [1]. It is characterized by extracellular senile plaques consisting mainly of 
aggregated amyloid-β (Aβ) and intracellular neurofibrillary tangles, containing the 
cytoskeletal protein tau [2]. ColostrininTM (CLN) has been shown to alleviate symptoms of 
Alzheimer’s disease [3]. The possible mechanism of action of CLN has been tested in vitro 
using cell lines, where it has been shown to protect against oxidative stress [12]. In particular, 
CLN has been found to prevent increases in the levels of reactive oxygen species (ROS) in 
response to hydrogen peroxide (H2O2) or Aβ in the SH-SY5Y human neuroblastoma cell line 
[4], although the precise mechanism by which these effects occur remains unclear. A key 
defense against ROS-induced damage is provided by the antioxidant enzyme superoxide 
dismutase 1 (SOD1) [5], and in AD patients increased levels of SOD1 have been found 
associated with plaques [6]. In the present study, we have investigated the mechanism of 
action of CLN using, for the first time, cultured primary rat hippocampal cells. 
 
Sprague Dawley rats of both sexes were used at embryonic day 18 (E18). All animal 
experimentation was carried out under UK Government Home Office guidelines. A protocol 
for the culture of dissociated rat hippocampal cells similar to that of Banker and Cowan [7] 
was used. Live cells were plated at a density of 20,000 cells/coverslip or 400,000 cells/well in 
BME (Basal Medium Eagle) containing 0.5% glucose, 1 mM sodium pyruvate, N2 
supplement, and 10% horse serum (Gibco/Invitrogen) on either poly-lysine coated 19 mm 
coverslips (VWR) for immunocytochemistry, or poly-lysine coated plates, for Western 
blotting. On the third day in vitro (DIV3), medium was replaced with BME including the 
supplement B27 (Gibco/Invitrogen). Bovine CLN was isolated from bovine colostrum and 
was supplied by ReGen Therapeutics. All the CLN used for the experiments reported in the 
present study was from the same batch. CLN was dissolved in phosphate buffered saline 
(PBS) at 2 mg/ml and diluted as appropriate. Aβ1-42 (Biosource) was dissolved in saline, 
diluted to 1 mg/ml in PBS, and incubated for 48 h at 37°C/5% CO2 with or without bovine 
CLN. Cultures were treated on DIV3 for 24 h for Western blotting experiments and for 48 h 
for immunocytochemistry experiments. 
 
Primary hippocampal cultures were fixed in 4% paraformaldehyde/PBS pH 7.4 for 1 h at 
room temperature (RT) and washed with PBS [8,9]. Rabbit polyclonal anti-GFAP (glial 
fibrillary acidic protein) antibody raised against cow GFAP (Dako-Cytomation 20334. 
1:1000) or mouse monoclonal anti-rat brain MAP-2 (microtubule associated protein) (Abcam 
ab11267. 1:1000) were applied overnight or for 48 h at RT, respectively. After washing in 
PBS, cultures were incubated with anti-rabbit biotinylated antibody (GE Healthcare 
RPN1004V1, 1:250), and strepavidin fluorescein (GE Healthcare RPN123V1. 1:100) for 
GFAP, or goat-anti-mouse amino-methyl-coumarin-acetate (AMCA) conjugated secondary 
antibody (Millipore AP130M, 1:100) for MAP-2. Immunopositive cells were counted using a 
square grid system on the stage manager function on an Olympus BX61 microscope at x400 
magnification. One hundred grid squares (347.64 µm by 260.73 µm) covering 9 mm2 of the 
coverslip were counted for each coverslip with at least three replicates for each condition per 
experiment. 
 
For Western blotting, treated cells were lysed with radio-immunoprecipitation assay lysis 
buffer containing protease inhibitors, sonicated and spun. Protein content was measured 
using a standard assay (Biorad), and samples were run at 100V for 2 h on 15% SDS 
polyacryamide gels, which were transferred to nitrocellulose membranes. Rabbit anti-SOD1 
antibody (Abcam ab51254) was applied at 1:25,000 for 1 h at RT before incubation in anti-
rabbit horseradish peroxidise conjugated secondary (Thermo Scientific-Pierce 31460) for 1 h 
at RT. Enhanced chemiluminescent reagent (ECL, from Perkin-Elma) was used to detect 
horseradish peroxidase and developing film was exposed to the blot. A second blocking step 
was carried out before rabbit anti-actin antibody (Rabbit monoclonal antibody against 
modified β-cytoplasmic actin Nterminal peptide, Sigma-Aldrich A1978) was applied 
overnight at 4°C. Developed films were scanned as greyscale images and Image J software 
was used to carry out densitometric analysis. Quantitative data were obtained in the form of 
cell counts or semi-quantitative densitometry values expressed as percentage of control for 
Western blots. Data were analyzed using one-way ANOVAs with a Bonferroni post-hoc test, 
or for non-parametric data using a Mann-Whitney test for comparisons between two groups. 
Data are expressed as means ±SEM. 
 
Treatment of cultures for 48 h with 25 µM Aβ1-42 resulted in MAP-2 positive cells (neurons) 
with shrunken appearance and reduced processes. These changes were much less apparent 
when 5 µg/ml bovine CLN was pre-incubated and co-administered with Aβ1-42. Densitometric 
quantification of Western blots (Figure 1A and 1B ) showed that 24 h treatment of primary 
rat hippocampal cultures with 10 µM Aβ1-42 caused a significant increase in the SOD1 protein 
levels (28%, P=0.037, Figure 1B) compared to untreated control cells. Pre-incubation and 
coadministration of 5 ng/ml or 5 µg/ml bovine CLN with Aβ1-42 reduced significantly the 
Aβ1-42- induced increase in SOD1 protein levels to control levels (P=0.05, Figure 1B). 
Quantification of MAP-2 cells (Figure 2A) revealed significant cell loss (44%, P=0.003) 
following treatment of dissociated hippocampal cultures with Aβ1-42. The reduction in MAP-
2 positive cells was alleviated when CLN at 5 µg/ml was pre-incubated and co-administered 
with Aβ1-42 (20%), compared to Aβ1-42 alone (Figure 2A) but this reduction was just below 
the 0.05 significance level. 
 The morphology of GFAP positive astrocytes was unaltered by treatment with Aβ1-42 
compared to control. .While treatment of cultures with 25 µM Aβ1-42 for 48 h led to a large 
reduction (54%) in the number of GFAP positive cells present in the cultures (Figure 2B), 
CLN at 5 µg/ml did not significantly reduce this loss (Figure 2B). 
 
The efficacy of CLN as a potential treatment for neurodegenerative disorders has been 
reviewed by Rattray [10], Boldogh and Kruzel [4], and Stewart [11]. Aβ1-42 is known to have 
a toxic effect on SHSY-5Y cells in culture when pre-incubated and co-administered with 
Aβ1-42 [12], an effect which is significantly alleviated by CLN. Moreover, 24 h pre-treatment 
of SHSY- 5Y cells with 5 µg/ml CLN was shown to reduce Aß1-40-induced apoptosis in 
human neuronal cells [13]. Our data confirm the efficacy of CLN in alleviating the adverse 
effects of Aβ1-42, in the present case its ability to protect primary hippocampal cells. 
Treatment of these cells with 25 µM Aβ1-42 caused a significant (44%) decrease in the 
number of MAP-2 positive neurons present in these primary cell cultures compared to 
controls. When Aβ1-42 was pre-incubated with bovine CLN before application to cultured 
cells, there was a reduction of this Aβ1-42-induced loss of MAP-2 positive neurons, and 
Western[j1] blot data demonstrated that pre-treatment with CLN also produced a significant 
reduction in the elevated levels of the antioxidant enzyme SOD1 seen in response to Aβ1-42 
treatment. These data confirm that CLN may prevent oxidative stress and hence that it could 
have prophylactic potential to alleviate neurodegenerative disorders. 
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FIGURE LEGENDS 
 
Figure 1. A) A representative Western blot for SOD1 for densitometric quantification of 
SOD1 from primary hippocampal cell line lysate after treatment with 5 ng/ml or 5 µg/ml 
bovine CLN, 10 µM Aβ1-42 or CLN pre-incubated and co-administered with Aβ1-42. B) SOD1 
protein levels in cultures treated with CLN at 5 ng/ml or 5 µg/ml. 10 µM Aβ1-42 increased 
SOD1 protein levels (P=0.037) and pre-incubation and co-administration of bovine CLN 
prevented this increase (P=0.05). n=3. * represents P<0.05. Error bars ±SEM. 
 
Figure 2. A) Quantification of the number of MAP-2 positive neurons and B) GFAP positive 
astrocytes in dissociated hippocampal cultures at 20,000 cells/well treated with Aβ1-42 and 
CLN. The number of MAP-2 positive cells (neurons) (A), and GFAP positive cells (glial 
cells) (B) decreased when cultures were treated with 25 µM Aβ1-42 alone (but was significant 
only for MAP-2 positive cells; P=0.03). The decrease in MAP-2 cells was alleviated when 
with Aβ1-42 and was co-incubated with CLN but much less so for GFAP. n=4 with at least 3 
replicates per condition in each experiment, error bars ±SEM. * indicates P=0.003. 
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